

GLOBAL LEADERS

in COVID-19 THERAPEUTICS



INDUSTRY Biopharmaceuticals

COMPANY STAGE Development stage with lead COVID-19 drugs ready for human clinical trials

MANAGEMENT

Darnisha Harrison

President & CEO

- Microbiologist/Chemist
- 8 years as biotech entrepreneur; 20 years in business development and licensing in pharmaceutical R&D
- Nationally recognized entrepreneur by Newsweek Magazine

Scott Michael, Ph.D.

Chief Scientific Officer

- Co-inventor of Ennaid's peptide technology
- Nearly 30 years of experience in discovery, antiviral and vaccine research and development

Janet VonKohn

Chief Global Strategist

- 25+ years as entrepreneur/global strategist
- Builds teams and commercial strategies to launch new drug products

William Howe

Chief Operating Officer

- Inventor of ROME, Ennaid's Digital Health diagnostic for traumatic brain injuries
- President & CEO of Mosquito-Borne Research Foundation
- Founder of VehWare

Chris Moreton, Ph.D.

Head of Pharmaceutical Sciences

- 30+ years of experience in pharmaceutical product development, clinical manufacturing, project management, technical transfer, cGMP and scale-up
- Sr. VP of Pharmaceuticals, CMC Expert

Bill Brock, Ph.D.

Head of Toxicology

- 30+ years of experience as a board-certified toxicologist with a wealth of experience in the pharma and consumer industries

KEY ADVISORS

Romeo Ibrahim, MS, Scientific Advisor
Gary Strauss, PhD, Scientific Advisor
Corey Hebert, MD, KOL & Medical Advisor
Michael Clark, Business Advisor

NUMBER OF EMPLOYEES

FT: 1; PT: 1; Contractors: 10+

BANK Chase

LAW FIRM Kilpatrick, Townsend & Stockton, LLP

CURRENT INVESTORS

Seed & angel funding: \$1.7MM

FINANCING REQUIRED

\$1B

USE OF FUNDS

75% Research & Development

15% Employees

5% Operational/Marketing

5% Legal/Other

BUSINESS DESCRIPTION & COMPANY

- Ennaid is a global biopharmaceutical company based in the **United States**, with subsidiaries in **Australia**, the **United Kingdom**, and **India**.
- Ennaid is developing a robust pipeline of therapeutics to treat COVID-19 and other deadly, infectious diseases affecting humans and animals worldwide using artificial intelligence (AI) drug discovery platforms.
- The company's immediate focus is developing an antiviral treatment for COVID-19, but also has a rich mosquito-borne disease pipeline of patented, new therapeutics targeting dengue virus, Zika virus, West Nile virus, and other viruses in the Flaviviridae family.
- Ennaid has a patented, repurposed drug that may treat advanced-stage colorectal cancer.
- Ennaid has two promising digital health products under development. One is a software-based diagnostic that measures traumatic brain injuries, such as concussions; the other is a clinical trial reporting software with telemedicine features.
- The Five Pillars of Ennaid are coronavirus, infectious disease, oncology, digital health and animal health.

PROBLEM

- SARS-CoV-2, the virus that causes COVID-19, is a global pandemic, infecting millions.
- More than 100 million infections have occurred globally, with nearly two and half million fatalities.
- Most COVID-19 infections are mild, moderate and/or asymptomatic.
- No effective, oral treatment currently exists for mild, moderate and asymptomatic infections.

SOLUTION/PRODUCTS/SERVICES

- Using AI-powered technologies, Ennaid's drug discovery scientists have identified more than 2,000 viral targets that potentially inhibit SARS-Cov-2 cell entry and replication. The discoveries include repurposed drugs, investigational drugs and new chemical entities that are all patent-pending.
- In vitro screening of some of these discoveries identified more than 30 promising COVID-19 treatments that block entry and/or replication of the virus.
- **ENU1400**, an investigational drug, and **ENU1600**, a repurposed drug, are Ennaid's lead compounds to treat COVID-19. Both drugs inhibit replication of the virus, ENU1400 by 90% and ENU1600 by 95%. ENU1400 shows dual action, also inhibiting COVID-19 entry by 60%. This indicates these compounds may effectively treat COVID-19, even in variant forms. ENU1400 and ENU1600:

are repurposed, making them easier, cheaper and quicker to get to market

have a long track record of excellent human safety

are orally administered and can be dosed at home

are analogous to Tamiflu, as Tamiflu is a treatment for influenza

will lower hospitalization rates

are oral treatments, which increases the likelihood of compliance due to vaccine resistance.

SPECIAL CAPABILITIES & EXPERTISE

- Collectively, Ennaid's team has over 200 years of experience in all phases of drug discovery & drug development, including structurally-based viral inhibitor design, toxicity testing, pharmacological optimization, animal model testing, drug formulation design, clinical trial design.
- ENU1400/1600 clinical trials will be in-home, self-dosing trials using Ennaid's HIPPA-certified, app-based clinical reporting software, iClickCare.
- iClickCare has advantages in today's world of quarantine and social distancing because it allows successful clinical trial monitoring and data collection.

BUSINESS MODEL

- Ennaid uses a virtual business model of collaborative partners to advance its product portfolio. These partners include Universidad de Católica San Antonio de Murcia in Spain, SUNY Buffalo, Pfizer, Catalent, University of Georgia, Scendeca in the UK and Southern Star Research in Australia. The national launch of its lead COVID-19 product is with a digital sales force likely led by OptimizeRx.
- Global launch of COVID-19 product will be under contractual alliance with a large pharmaceutical company for marketing and distribution. Government negotiations in socialized settings will occur simultaneously along with utilization of a managed care team to roll onto insurance formularies where necessary. Pricing is to be affordably based on pharmaco-economist's average suggested pricing balanced with R&D expenses.

COMMERCIAL-READY COVID-19 THERAPEUTIC TIMELINE

May 2021: IND filing of ENU1600, Ennaid's lead COVID-19 therapeutics

June 2021 - September 2021: Combined Phase 2b/3 at-home, self-dosing human clinical trial for ENU1600

September 2021: New Drug Application filing for ENU1600

November 2021: Commercial launch & distribution of ENU1600



Darnisha Harrison



770.337.7778



404.745.0800



darnisha@ennaidthera.com



2792 Webb Bridge RD, Alpharetta, GA 30009



www.ennaidthera.com